Sellas Life Sciences Group Inc (SLS) Stock Analysis

Sellas Life Sciences Group Inc (SLS) is a publicly traded company in the HEALTHCARE sector. It trades at $8.33, carries a market capitalization of $1.69B. This page summarizes the public market data, fundamentals, and frequently asked questions for SLS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Sellas Life Sciences Group Inc currently has a Bullish sentiment score of 0.30.

About Sellas Life Sciences Group Inc

SELLAS Life Sciences Group Inc. is a forward-thinking biopharmaceutical company based in New York, specializing in the development of groundbreaking cancer immunotherapies designed to tackle various oncological indications. By leveraging the body's immune system to effectively combat cancer, Sellas is advancing a proprietary pipeline of innovative treatments that address pressing medical needs. With its strategic focus and commitment to revolutionizing cancer care, Sellas positions itself as ...

GNG Research Analysis

GNG Research scores Sellas Life Sciences Group Inc (SLS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SLS.

Frequently Asked Questions

Does SLS pay dividends?

Sellas Life Sciences Group Inc (SLS) does not currently pay a regular dividend.

What is SLS's market cap?

Sellas Life Sciences Group Inc (SLS) has a market capitalization of $1.69B with a current stock price of $8.33.